AstraZeneca in deal with Immunocore to develop novel cancer therapies

8 January 2014

UK privately-held biotech firm Immunocore has signed an oncology research collaboration and licensing agreement with MedImmune, the global biologics R&D unit of Anglo-Swedish pharma major AstraZeneca (LSE: AZN).

Both companies will research and develop novel cancer therapies using Immunocore’s immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) technology.

The deal comes hot on the heels of AstraZeneca announcement yesterday of a link up with UK-based Horizon Discovery (see separate story) and adds to fast-growing Immunocore’s agreements with UK drug giant GlaxoSmithKline (LSE: GSK) focused on developing novel biological drugs called ImmTACs to treat cancer and viral disease worth a potential of over $400 million (The Pharma Letter July 9, 2013) and Switzerland’s Roche (ROG: SIX) for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology, also worth more than $300 million (TPL July 1).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK